DXDaqian Xu

Daqian Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daqian Xu has a total of 254 co-authors. Here are the top co-authors by number of shared publications:

  • Zhimin Lu

    Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China

    17 shared publications
  • Zheng Wang

    Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China

    15 shared publications
  • Yuran Duan

    Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China

    11 shared publications
  • Guimei Ji

    Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China

    10 shared publications
  • Liwei Xiao

    Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China

    10 shared publications
  • Yuli Shen

    Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China

    10 shared publications

Latest Publications

  • MMSDH facilitates ACSL4 propionylation to counteract ferroptosis upon hypoxia and impairs PDAC chemotherapy efficacy

    by Peixiang Zheng, Yanni Lin, Meiyin Zhang, Zhiyuan Tang, Wenxing Qin, Min Xiao, Xue Sun, Yuli Shen, Zhiqiang Hu, Shuo Ru, et al.

    Limited efficacy of neoadjuvant chemotherapy (NAC) in pancreatic ductal adenocarcinoma (PDAC) underscores the need for novel combination strategies and a deeper understanding of metabolic determinants of chemoresistance. Here we identify methylmalonate semialdehyde dehydrogenase (MMSDH), a valine catabolism enzyme, as a driver of gemcitabine (GC) resistance. Hypoxia induces GCN5-mediated lactylation of MMSDH at K113. Lactylated MMSDH interacts with acyl-CoA synthetase long-chain family member 4 (ACSL4), generating propionyl-CoA to facilitate KAT8-mediated ACSL4 K606 propionylation. This modification enhances ACSL4–HSC70 binding, promoting its degradation through chaperone-mediated autophagy. Critically, this MMSDH-mediated ACSL4 propionylation correlates with low ACSL4 levels and poor NAC response in recipients. Combining dietary valine restriction with GC synergistically induces ferroptosis and suppresses tumor growth. Blocking MMSDH-K113la disrupts this axis, potentiating GC-induced ferroptosis and inhibiting tumor progression. These findings reveal a previously unknown mechanism of ferroptosis evasion through valine metabolism and ACSL4 regulation, nominating the GCN5–MMSDH–ACSL4 axis as a therapeutic target to enhance PDAC chemosensitivity.


  • Open Access

    Methyl indole-3-acetate contributes to strain-specific anti-inflammatory effects of Lactiplantibacillus plantarum

    by Kailin Liu, Meng Wang, Xinyi Zhu, Libin Pan, Lichao Wang, Wu Bao, Bingqing Hang, Xianjiong Chen, Guifang Li, Daqian Xu, et al.

    Lactiplantibacillus plantarum is a widely recognized probiotic with anti-inflammatory potential, yet its efficacy varies among strains and the underlying determinants remain poorly defined. Here, we identify methyl indole-3-acetate (MIA), a previously uncharacterized microbial metabolite, as a contributor to the strain-specific anti-inflammatory effects of L. plantarum . Strains with higher MIA production show stronger protection against colitis in mice, whereas deletion of the key biosynthetic enzyme eliminates this protective effect. Mechanistically, MIA epigenetically activates the transcription of lncRNA Snhg9 by promoting histone H4K8 acetylation at its promoter, an effect mediated through direct inhibition of HDAC1. In turn, Snhg9 suppresses NF-κB signaling by enhancing the deacetylase activity of SIRT1, thereby attenuating inflammatory responses. Together, our findings support a role for MIA in shaping strain-dependent host responses to L. plantarum , uncover a lncRNA-mediated host–microbe regulatory pathway, and provide a framework for further investigation of strain-specific probiotic function in inflammatory disorders.

  • Top Cited Papers
    Open Access

    Tumor heterogeneity: development, mechanisms, and therapeutic implications

    by Jianhong Zhang, Heng Li, Shuo Ru, Hui Feng, Junsong Guo, Danlei Sun, Tingxiu Xiang, Daqian Xu, Yang Luo

    Tumor heterogeneity is a fundamental hallmark of cancer that drives progression, metastasis and therapeutic resistance. This diversity originates from persistent genomic instability, dynamic clonal evolution, and cancer stem cell plasticity, which are further amplified through complex crosstalk within the tumor microenvironment. While conventional therapies effectively eliminate certain tumor cell populations, residual resistant subclones frequently lead to disease relapse. Recent breakthroughs in single-cell multi-omics, spatial transcriptomics, and liquid biopsy now enable a comprehensive, multidimensional dissection of tumor heterogeneity across molecular, cellular, spatial, and temporal scales. These approaches reveal real-time dynamics of tumor evolution, providing new opportunities for therapeutic intervention. This review synthesizes key advances in understanding tumor heterogeneity: from its cellular origins and molecular mechanisms to its multidimensional manifestation in the tumor microenvironment and from metastatic heterogeneity to the fundamental causes of treatment resistance. We critically examine how these insights are informing novel therapeutic paradigms—including targeting clonal cooperative networks, modulating epigenetic plasticity and reprogramming metabolic adaptations. Finally, we outline future pathways toward precision medicine through the integration of multi-omics data and dynamic monitoring technologies. Ultimately, overcoming tumor heterogeneity necessitates reconceptualizing cancer not as a static collection of cells but as a dynamically evolving ecosystem.


  • Nuclear OXCT1 attenuates histone β-hydroxybutyrylation-mediated MHC-I transcription

    by Zhiqiang Hu, Wei Lv, Ting Wen, Junyi Sun, Guimei Ji, Shuo Ru, Xue Sun, Zheng Wang, He Ren, Yudi Zhang, et al.

    Understanding of the metabolic determinants influencing immunotherapy responsiveness remains limited. Here we performed a multiomics analysis of tumor biopsies from patients with hepatocellular carcinoma (HCC) treated with immune checkpoint blockade (ICB) and revealed that heightened expression of OXCT1, a rate-limiting enzyme in ketone body metabolism, was negatively correlated with ICB efficacy, whereas its metabolic substrate, β-hydroxybutyrate (BHB), displayed an opposite effect. Mechanistically, glucose deprivation in HCC cells promotes AMPK-mediated OXCT1 S113 phosphorylation, which exposes the nuclear localization sequence of OXCT1 to trigger its nuclear translocation. Nucleus-translocated OXCT1 associates with IRF1 to locally consume BHB and suppress histone H3K9 BHB at the major histocompatibility complex class I (MHC-I) and chemokine gene loci, leading to repressed transcription of these immune genes. Targeting the AMPK-OXCT1-IRF1 axis sensitizes tumor cells to ICB upon ketogenic diet. These findings reveal a mechanism by which a non-canonical function of nuclear OXCT1 coordinates the interplay between ketone body metabolic reprogramming and immunotherapy responsiveness.


  • Open Access

    Hepatic SNHG9 links gut microbiota to liver protection in drug-induced liver injury

    by Wu Bao, Bingqing Hang, Danyi Zeng, Jiajie Mao, Li-Bin Pan, Lichao Wang, Guangyi Xu, Meng Wang, Kailin Liu, Xianjiong Chen, et al.

    Drug-induced liver injury (DILI) is a leading cause of acute liver failure, posing a significant public health burden. Emerging evidence underscores the gut microbiota as a critical environmental factor that profoundly influences liver function and DILI progression, yet the underlying mechanisms remain poorly understood. Here, we identify hepatic long non-coding RNA SNHG9 as a key mediator linking the gut microbiota to acetaminophen (APAP)-induced liver injury. Upregulation of hepatic SNHG9 protects against hepatotoxicity by activating MAS, a G protein-coupled receptor that facilitates the clearance of cellular damage via enhanced autophagy. Mechanistically, SNHG9 binds to insulin-like growth factor 2 mRNA-binding protein 2 (IMP2), enhancing its interaction with MYC mRNA and suppressing MYC translation. Since MYC acts as a transcriptional repressor of the MAS1 gene, this suppression leads to upregulated MAS expression. Notably, hepatic SNHG9 expression is modulated by the gut microbiota, particularly through the metabolite 2-hydroxy 2-methylbutyric acid (HMB). Supplementation with HMB or HMB-producing microbes robustly induces hepatic SNHG9 expression and attenuates APAP-induced liver injury. Our findings unveil a previously unrecognized gut-liver axis and provide mechanistic insight into how gut microbiota regulate hepatic stress responses, suggesting potential avenues for modulating this pathway in drug-induced liver injury.


  • Open Access

    INSIG1/2 succination mediated by the moonlighting function of ADSL promotes lipogenesis and liver tumorigenesis

    by Yuran Duan, Shuo Wang, Jianyu Liu, Wenxing Qin, Yuli Shen, Yueru Hou, Xue Sun, Yanni Lin, Zhiqiang Hu, Bofei Dong, et al.

    Aerobic glycolysis supports tumor growth, but how tumor cells sense glucose to coordinate biosynthesis remains largely unclear. Here we show that in hepatocellular carcinoma cells, glucose-activated PKCε phosphorylates the purine synthesis enzyme ADSL, triggering its translocation to the endoplasmic reticulum. ADSL then promotes succination of INSIG1/2, which disrupts the interaction between INSIG proteins and SCAP, leading to the translocation of the SCAP-SREBP complex to the Golgi, the activation of SREBP-1 and the transcription of downstream lipogenesis-related genes, proliferation of tumor cells, and tumorigenesis in mice. Through virtual screening, we identify Elsulfavirine, an approved HIV drug, which blocks ADSL-INSIG interaction and suppresses SREBP-1 activation induced by glucose. Combining Elsulfavirine with Lenvatinib synergistically inhibits tumor growth. Clinically, ADSL phosphorylation and INSIG succination correlate with SREBP-1 activation and poor prognosis in human HCC. In summary, these findings reveal a repurposing mechanism by which tumor cells coordinate glucose metabolism and lipogenesis via a moonlighting function of ADSL and underscore a repurposing strategy for liver cancer therapy.


  • Open Access

    Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells

    by Bo-Yan Chen, Hong Zhu, Yu-Lin Li, Jun Zhang, Shuo Xu, Lu-Jun Zhou, Lin-Juan Du, Ting Liu, Xue-Nan Sun, Guo-Cai Tian, et al.

    BACKGROUND: Myocardial infarction (MI) is a high-prevalence disease that threatens human survival and quality of life worldwide. Considerable evidence has suggested that periodontitis (PD) is detrimental to MI. However, the direct impact of PD on MI is unclear; which oral pathobionts contribute to and how microbial signals regulate the pathogenesis of MI remain obscure. METHODS: The effect of PD on MI was assessed in a mouse model that combined ligature-induced PD with MI. Ectopic accumulation of oral pathobionts in infarcted hearts was identified by bacterial sequencing and fluorescence in situ hybridization. Oral pathobionts–reactive B2 cells detrimental for MI were determined by flow cytometry and verified in gnotobiotic mice. Several mouse strains, including CD45.1, Kaede, and knockout strains for Ighm, Rag1, C-X-C motif chemokine ligand 13, S1pr, interleukin-6, and tumor necrosis factor-α, were used for mechanistical exploration. Mutant strains of Fusobacterium nucleatum and Porphyromonas gingivalis deficient in adhesion proteins were generated to investigate bacterial mechanism involved in MI exacerbation. Patients with MI with or without PD were recruited to test the deteriorating impact of PD on MI and the association between oral pathobionts and cardiac function. RESULTS: Ligature-induced PD and subgingival plaques of patients with PD exacerbated MI in mice by oral pathobionts. Prevotella intermedia , Fusobacterium nucleatum , Selenomonas sputigena , Porphyromonas gingivalis , and Bacteroides plebeius expanded in the oral cavity and ectopically accumulated in the infarcted hearts through impairment of epithelial and endothelial cell barriers. These oral pathobionts mobilized B cells, particularly B2 cells that produced interleukin-6 and tumor necrosis factor-α, to aggravate MI. Mechanistically, oral pathobiont–promoted B cells egress from cervical lymph nodes by a sphingosine-1-phosphate–sphingosine-1-phosphate receptor axis and infiltrate infarcted hearts by a C-X-C motif chemokine ligand 13–C-X-C motif chemokine receptor 5 axis. CONCLUSIONS: Oral pathobionts and proinflammatory B2 cells significantly exacerbate MI, supporting the oral-heart axis as a novel pathogenic pathway. Interventions targeting PD, oral pathobionts, or related immunological mechanisms may improve the therapy of MI.


  • Circadian genes CLOCK and BMAL1 in cancer: mechanistic insights and therapeutic strategies

    by Yuli Shen, Yuqian Zhao, Xue Sun, Guimei Ji, Daqian Xu, Zheng Wang

    The circadian clock is a highly conserved timekeeping system in organisms, which maintains physiological homeostasis by precisely regulating periodic fluct


  • Open Access

    Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation

    by Shudi Luo, Huang Yang, Xiaoming Jiang, Zheng Wang, Xuxiao He, Ying Meng, Shan Li, Min Li, Daqian Xu, Zhengwei Mao, et al.

    Tumor cells have substantially increased lipid biogenesis, which is primarily regulated by the activation of sterol regulatory element‐binding protein (SREBP). However, whether SREBP regulation can be targeted for cancer treatment remains unclear. Here, it is demonstrated that treating tumor cells with a peptide that replicates the amino acid sequence in Insig1/2 loop 1, which is the region where Insig1/2 interacts with AKT‐phosphorylated phosphoenolpyruvate carboxykinase 1 (PCK1), inhibits the IGF1‐induced interaction between PCK1 and Insig1/2. Consequently, this treatment abrogates PCK1‐mediated phosphorylation of Insig1 at S207 and Insig2 at S151, reduces the nuclear accumulation of SREBP1, and decreases SREBP1 activity‐dependent expression of lipid synthesis genes, lipid accumulation, and tumor cell proliferation. Intravenous administration of engineered liposomal nanoparticles (LNP)‐encapsulated Insig1/2 loop 1 peptide effectively suppresses tumor growth and extends mouse survival without apparent adverse effects. The peptide treatment, when combined with the receptor tyrosine kinase inhibitor lenvatinib or the anti‐obesity medication semaglutide, results in additive tumor inhibition. These findings highlight the potential of LNP‐Insig1/2 loop 1 peptide administration to inhibit SREBP activity—traditionally regarded as untargetable—for the treatment of human cancer.


  • PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation

    by Peixiang Zheng, Zhiqiang Hu, Yuli Shen, Lina Gu, Yuan Ouyang, Yuran Duan, Guimei Ji, Bofei Dong, Yanni Lin, Ting Wen, et al.

    Tumor cells adapt to the inflammatory tumor microenvironment (TME) and develop resistance to immunotherapy, with ferroptosis being a major form of tumor cell death. However, the mechanisms by which tumor cells coordinate TME stimuli and their unique metabolic traits to evade ferroptosis and develop resistance to immunotherapy remain unclear. Here we showed that interferon-γ (IFNγ)-activated calcium/calmodulin-dependent protein kinase II phosphorylates phosphoserine aminotransferase 1 (PSAT1) at serine 337 (S337), allowing it to interact with glutathione peroxidase 4 (GPX4) and stabilize the protein, counteracting ferroptosis. PSAT1 elevates GPX4 stability by promoting α-ketoglutarate-dependent PHD3-mediated GPX4 proline 159 (P159) hydroxylation, disrupting its binding to HSC70 and inhibiting autophagy-mediated degradation. In mice, reconstitution of PSAT1 S337A or GPX4 P159A promotes ferroptosis and suppresses triple-negative breast cancer (TNBC) progression. Blocking PSAT1 pS337 with CPP elevates IFNγ-induced ferroptosis and enhances the efficacy of programmed cell death protein 1 (PD-1) antibodies in TNBC. Additionally, PSAT1-mediated GPX4 hydroxylation correlates with poor immunotherapy outcomes in patients with TNBC, highlighting PSAT1’s noncanonical role in suppressing ferroptosis and immunotherapy sensitivity.